Načítá se...
Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials
BACKGROUND: Cystic fibrosis (CF) pulmonary exacerbations can be serious respiratory events and reduction in exacerbation rate or risk are important efficacy endpoints for CF therapeutic trials. Variability in exacerbation diagnoses and treatment have led drug developers to employ “objective” exacerb...
Uloženo v:
| Vydáno v: | J Cyst Fibros |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
European Cystic Fibrosis Society. Published by Elsevier B.V.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7362840/ https://ncbi.nlm.nih.gov/pubmed/32682670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcf.2020.07.008 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|